The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Myeloproliferative Disorders Drugs-Global Market Insights and Sales Trends 2025
Synopsis
hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
The global Myeloproliferative Disorders Drugs market size is expected to reach US$ 7581.8 million by 2029, growing at a CAGR of 2.6% from 2023 to 2029. The market is mainly driven by the significant applications of Myeloproliferative Disorders Drugs in various end use industries. The expanding demands from the Hospitals and Pharmacy, are propelling Myeloproliferative Disorders Drugs market. Ph+ CML, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Ph- MPN segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Myeloproliferative Disorders Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Myeloproliferative Disorders Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Myeloproliferative Disorders Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Myeloproliferative Disorders Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Myeloproliferative Disorders Drugs covered in this report include Celgene, Bristol-Myers Squibb, Gamida Cell, Incyte, Geron, Promedior and Johnson and Johnson, etc.
The global Myeloproliferative Disorders Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson
Global Myeloproliferative Disorders Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Myeloproliferative Disorders Drugs market, Segment by Type:
Ph+ CML
Ph- MPN
Global Myeloproliferative Disorders Drugs market, by Application
Hospitals
Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Myeloproliferative Disorders Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
The global Myeloproliferative Disorders Drugs market size is expected to reach US$ 7581.8 million by 2029, growing at a CAGR of 2.6% from 2023 to 2029. The market is mainly driven by the significant applications of Myeloproliferative Disorders Drugs in various end use industries. The expanding demands from the Hospitals and Pharmacy, are propelling Myeloproliferative Disorders Drugs market. Ph+ CML, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Ph- MPN segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Myeloproliferative Disorders Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Myeloproliferative Disorders Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Myeloproliferative Disorders Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Myeloproliferative Disorders Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Myeloproliferative Disorders Drugs covered in this report include Celgene, Bristol-Myers Squibb, Gamida Cell, Incyte, Geron, Promedior and Johnson and Johnson, etc.
The global Myeloproliferative Disorders Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson
Global Myeloproliferative Disorders Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Myeloproliferative Disorders Drugs market, Segment by Type:
Ph+ CML
Ph- MPN
Global Myeloproliferative Disorders Drugs market, by Application
Hospitals
Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Myeloproliferative Disorders Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Myeloproliferative Disorders Drugs
1.1 Myeloproliferative Disorders Drugs Market Overview
1.1.1 Myeloproliferative Disorders Drugs Product Scope
1.1.2 Myeloproliferative Disorders Drugs Market Status and Outlook
1.2 Global Myeloproliferative Disorders Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Myeloproliferative Disorders Drugs Market Size by Region (2018-2029)
1.4 Global Myeloproliferative Disorders Drugs Historic Market Size by Region (2018-2023)
1.5 Global Myeloproliferative Disorders Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Myeloproliferative Disorders Drugs Market Size (2018-2029)
1.6.1 North America Myeloproliferative Disorders Drugs Market Size (2018-2029)
1.6.2 Europe Myeloproliferative Disorders Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Myeloproliferative Disorders Drugs Market Size (2018-2029)
1.6.4 Latin America Myeloproliferative Disorders Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Myeloproliferative Disorders Drugs Market Size (2018-2029)
2 Myeloproliferative Disorders Drugs Market by Type
2.1 Introduction
2.1.1 Ph+ CML
2.1.2 Ph- MPN
2.2 Global Myeloproliferative Disorders Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Myeloproliferative Disorders Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Myeloproliferative Disorders Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Myeloproliferative Disorders Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Myeloproliferative Disorders Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Myeloproliferative Disorders Drugs Revenue Breakdown by Type (2018-2029)
3 Myeloproliferative Disorders Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Pharmacy
3.2 Global Myeloproliferative Disorders Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Myeloproliferative Disorders Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Myeloproliferative Disorders Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Myeloproliferative Disorders Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Myeloproliferative Disorders Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Myeloproliferative Disorders Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Myeloproliferative Disorders Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Myeloproliferative Disorders Drugs Revenue Breakdown by Application (2018-2029)
4 Myeloproliferative Disorders Drugs Competition Analysis by Players
4.1 Global Myeloproliferative Disorders Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myeloproliferative Disorders Drugs as of 2022)
4.3 Date of Key Players Enter into Myeloproliferative Disorders Drugs Market
4.4 Global Top Players Myeloproliferative Disorders Drugs Headquarters and Area Served
4.5 Key Players Myeloproliferative Disorders Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Myeloproliferative Disorders Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Celgene
5.1.1 Celgene Profile
5.1.2 Celgene Main Business
5.1.3 Celgene Myeloproliferative Disorders Drugs Products, Services and Solutions
5.1.4 Celgene Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Celgene Recent Developments
5.2 Bristol-Myers Squibb
5.2.1 Bristol-Myers Squibb Profile
5.2.2 Bristol-Myers Squibb Main Business
5.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Products, Services and Solutions
5.2.4 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Bristol-Myers Squibb Recent Developments
5.3 Gamida Cell
5.3.1 Gamida Cell Profile
5.3.2 Gamida Cell Main Business
5.3.3 Gamida Cell Myeloproliferative Disorders Drugs Products, Services and Solutions
5.3.4 Gamida Cell Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Incyte Recent Developments
5.4 Incyte
5.4.1 Incyte Profile
5.4.2 Incyte Main Business
5.4.3 Incyte Myeloproliferative Disorders Drugs Products, Services and Solutions
5.4.4 Incyte Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Incyte Recent Developments
5.5 Geron
5.5.1 Geron Profile
5.5.2 Geron Main Business
5.5.3 Geron Myeloproliferative Disorders Drugs Products, Services and Solutions
5.5.4 Geron Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Geron Recent Developments
5.6 Promedior
5.6.1 Promedior Profile
5.6.2 Promedior Main Business
5.6.3 Promedior Myeloproliferative Disorders Drugs Products, Services and Solutions
5.6.4 Promedior Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Promedior Recent Developments
5.7 Johnson and Johnson
5.7.1 Johnson and Johnson Profile
5.7.2 Johnson and Johnson Main Business
5.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Products, Services and Solutions
5.7.4 Johnson and Johnson Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Johnson and Johnson Recent Developments
6 North America
6.1 North America Myeloproliferative Disorders Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Myeloproliferative Disorders Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Myeloproliferative Disorders Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Myeloproliferative Disorders Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Myeloproliferative Disorders Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Myeloproliferative Disorders Drugs Market Dynamics
11.1 Myeloproliferative Disorders Drugs Industry Trends
11.2 Myeloproliferative Disorders Drugs Market Drivers
11.3 Myeloproliferative Disorders Drugs Market Challenges
11.4 Myeloproliferative Disorders Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
